Research and Development Investment: Teva Pharmaceutical Industries Limited vs Summit Therapeutics Inc.

Teva vs. Summit: A Decade of R&D Investment Trends

__timestampSummit Therapeutics Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014156350761488000000
Thursday, January 1, 2015239436011525000000
Friday, January 1, 2016236891112111000000
Sunday, January 1, 2017410061141848000000
Monday, January 1, 2018513791061213000000
Tuesday, January 1, 2019327055931010000000
Wednesday, January 1, 202053274000997000000
Friday, January 1, 202185352000967000000
Saturday, January 1, 202251999000838000000
Sunday, January 1, 202359471000953000000
Monday, January 1, 2024998000000
Loading chart...

Igniting the spark of knowledge

A Decade of R&D Investment: Teva vs. Summit

In the ever-evolving pharmaceutical industry, research and development (R&D) investment is crucial for innovation and growth. Over the past decade, Teva Pharmaceutical Industries Limited and Summit Therapeutics Inc. have demonstrated contrasting R&D strategies.

Teva, a global leader, consistently invested heavily in R&D, peaking in 2016 with a 63% increase from 2014. However, by 2022, their investment had decreased by 60%, reflecting strategic shifts or market challenges. In contrast, Summit Therapeutics, a smaller player, showed a steady increase in R&D spending, with a remarkable 283% growth from 2014 to 2023. This indicates a strong commitment to innovation and potential market expansion.

These trends highlight the dynamic nature of pharmaceutical R&D investment, where strategic decisions can significantly impact a company's competitive edge and market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025